NASDAQ:ALIM - Alimera Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.09 +0.05 (+4.81 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$1.04
Today's Range$1.04 - $1.10
52-Week Range$0.74 - $1.65
Volume84,378 shs
Average Volume97,959 shs
Market Capitalization$80.19 million
P/E Ratio-3.76
Dividend YieldN/A
Beta1.56
Alimera Sciences logoAlimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat DME. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Debt-to-Equity Ratio-0.62
Current Ratio4.81
Quick Ratio4.64

Price-To-Earnings

Trailing P/E Ratio-3.76
Forward P/E Ratio-3.89
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.91 million
Price / Sales2.13
Cash FlowN/A
Price / CashN/A
Book Value($0.78) per share
Price / Book-1.40

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-22,000,000.00
Net Margins-58.70%
Return on EquityN/A
Return on Assets-29.73%

Miscellaneous

Employees126
Outstanding Shares70,040,000
Market Cap$80.19

Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) announced its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.02. The biopharmaceutical company had revenue of $9.80 million for the quarter, compared to the consensus estimate of $9.80 million. View Alimera Sciences' Earnings History.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Alimera Sciences.

What price target have analysts set for ALIM?

3 brokerages have issued 12-month target prices for Alimera Sciences' stock. Their predictions range from $2.75 to $3.00. On average, they anticipate Alimera Sciences' share price to reach $2.9167 in the next year. This suggests a possible upside of 167.6% from the stock's current price. View Analyst Ratings for Alimera Sciences.

What is the consensus analysts' recommendation for Alimera Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Alimera Sciences stock?

Here are some recent quotes from research analysts about Alimera Sciences stock:
  • 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (7/10/2018)
  • 2. HC Wainwright analysts commented, "We note that less than a third of chronic DME patients in England and Wales have an artificial lens. Therefore, if reimbursement of Iluvien is available to all DME patients in UK, Alimera’s revenue from UK could increase significantly. Management expects the Technology Assessment 301 part-appraisal to be completed in 2019. In the wake of this update, we reiterate our Buy rating and $2.50 price target." (6/12/2018)

Who are some of Alimera Sciences' key competitors?

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the folowing people:
  • Mr. Charles Daniel Myers, Co-Founder, CEO & Director (Age 64)
  • Mr. Richard S. Eiswirth Jr., Pres & CFO (Age 50)
  • Dr. Kenneth Green, Sr. VP & Chief Scientific Officer (Age 60)
  • Mr. David R. Holland, Co-Founder and Sr. VP of Sales & Marketing (Age 54)
  • Mr. Jeffrey W. Burris, VP, Gen. Counsel & Sec. (Age 46)

Has Alimera Sciences been receiving favorable news coverage?

News stories about ALIM stock have been trending somewhat positive on Friday, Accern reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alimera Sciences earned a news sentiment score of 0.15 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.52 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $1.09.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $80.19 million and generates $35.91 million in revenue each year. The biopharmaceutical company earns $-22,000,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Alimera Sciences employs 126 workers across the globe.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]


MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.